The company declared the results after market hours on Tuesday, 8 November 2011.
Meanwhile, the BSE Sensex was up 18.44 points, or 0.1% to 17,587.97.
On BSE, 2.87 lakh shares were traded in the counter as against average daily volume of 1.66 lakh shares in the past one quarter.
The stock hit high of Rs 121 and a low of Rs 117.05 so far during the day. The stock had hit a 52-week low of Rs 116.55 on 10 October 2011. The stock had hit an all time high of Rs 275 on 5 January 2011.
The mid-cap stock had underperformed the market over the past one month till 8 November 2011, gaining 2.54% compared with the Sensex's 8.24% return. The scrip had also underperformed the market in past one quarter, declining 21.82% as against 3.41% gain in the Sensex.
The company has an equity capital of Rs 29.11 crore. Face value per share is Re 1.
Aurobindo Pharma's consolidated net sales declined 3.4% to Rs 1075.30 crore in Q2 September 2011 over Q2 September 2010.
Commenting on the results, Mr Ramprasad Reddy, Chairman, Aurobindo Pharma said, The first half of the current fiscal has been challenging on account of lower formulations sales, full impact of the USFDA alert on our unit VI cephalosporin manufacturing facility, subdued demand environment in Europe, disruption in operations due to regional unrest and notional loss on restatement of foreign currency borrowings. We are confident to deliver on better operational performance in the coming quarters with profitable sales mix”.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has robust product portfolio spread over major product areas encompassing CVS, CNS, anti-retroviral, antibiotics, gastroenterologicals, anti-diabetics and anti-allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs & Formulations and has global presence with own infrastructure, strategic alliances, subsidiaries & joint ventures.